Antiplatelet Agents for the Prevention of Pre-Eclampsia

ABSTRACT

Pre-eclampsia (P-EC) remains a significant problem in modern obstetrics occurring in 2 to 4% of women. The disease is still responsible for 60,000 maternal deaths worldwide annually. An increased understanding of the underlying pathophysiology has resulted in a more scientific approach to prophylaxis and prevention, yet the underlying disease mechanisms are not fully understood. The role of combining good prediction with prevention has yet to be established but has the potential to target health resources far more efficiently. Good prediction may also impact on tailoring antenatal care appropriately, with prophylactic measures for high-risk women becoming the highly preferred management option. Antiplatelet agents reduce the incidence and complications of P-EC and should be considered prophylactically in those at high risk of the disease.

KEYWORDS

Eclampsia - hypertension - aspirin - antiplatelet - pre-eclampsia - pregnancy - proteinuria

REFERENCES

• 1 AbouZahr C, Wardlaw T. Maternal mortality in 2000: estimates developed by WHO, UNICEF, and UNFPA. Available at: http://www.who.int/reproductive-health/publications/maternal_mortality_2000/maternal_mortality_2000.pdf Accessed July 12, 2004
• 2 De Vivo A, Baviera G, Giordano D, Todarello G, Corrado F, D'anna R. Endoglin, PIGF and sFlt-1 as markers for predicting pre-eclampsia.  Acta Obstet Gynecol Scand. 2008;  87 (8) 837-842
• 3 Janes S L, Kyle P M, Redman C, Goodall A H. Flow cytometric detection of activated platelets in pregnant women prior to the development of pre-eclampsia.  Thromb Haemost. 1995;  74 (4) 1059-1063
• 4 Bar J, Ben-Haroush A, Feldberg D, Hod M. The pharmacologic approach to the prevention of preeclampsia: from antiplatelet, antithrombosis and antioxidant therapy to anticonvulsants.  Curr Med Chem Cardiovasc Hematol Agents. 2005;  3 (3) 181-185
• 5 Bussolino F, Benedetto C, Massobrio M, Camussi G. Maternal vascular prostacyclin activity in pre-eclampsia.  Lancet. 1980;  2 (8196) 702
• 6 Duley L, Henderson-Smart D J, Meher S, King J F. Antiplatelet agents for preventing pre-eclampsia and its complications.  Cochrane Database Syst Rev. 2007;  2 (2) CD004659
• 7 Askie L M, Duley L, Henderson-Smart D J, Stewart L A. PARIS Collaborative Group . Antiplatelet agents for prevention of pre-eclampsia: a meta-analysis of individual patient data.  Lancet. 2007;  369 (9575) 1791-1798
• 8 Coomarasamy A, Honest H, Papaioannou S, Gee H, Khan K S. Aspirin for prevention of preeclampsia in women with historical risk factors: a systematic review.  Obstet Gynecol. 2003;  101 (6) 1319-1332
• 9 Cnossen J S, Morris R K, ter Riet G et al. Use of uterine artery Doppler ultrasonography to predict pre-eclampsia and intrauterine growth restriction: a systematic review and bivariable meta-analysis.  CMAJ. 2008;  178 (6) 701-711
• 10 Coomarasamy A, Papaioannou S, Gee H, Khan K S. Aspirin for the prevention of preeclampsia in women with abnormal uterine artery Doppler: a meta-analysis.  Obstet Gynecol. 2001;  98 (5 Pt 1) 861-866
• 11 Bujold E, Morency A M, Roberge S, Lacasse Y, Forest J C, Giguère Y. Acetylsalicylic acid for the prevention of preeclampsia and intra-uterine growth restriction in women with abnormal uterine artery Doppler: a systematic review and meta-analysis.  J Obstet Gynaecol Can. 2009;  31 (9) 818-826
• 12 Poston L, Briley A L, Seed P T, Kelly F J, Shennan A H. Vitamins in Pre-eclampsia (VIP) Trial Consortium . Vitamin C and vitamin E in pregnant women at risk for pre-eclampsia (VIP trial): randomised placebo-controlled trial.  Lancet. 2006;  367 (9517) 1145-1154
• 13 Hofmeyr G J, Atallah A N, Duley L. Calcium supplementation during pregnancy for preventing hypertensive disorders and related problems.  Cochrane Database Syst Rev. 2006;  3 CD001059
• 14 Chappell L C, Seed P, Enye S, Briley A L, Poston L, Shennan A H. Clinical and geographical variation in prophylactic and therapeutic treatments for pre-eclampsia in the UK.  BJOG. 2010;  117 (6) 695-700